{"id":"W2547680646","doi":"10.1093/annonc/mdw435.39","title":"NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Internal medicine; Ipilimumab; Response Evaluation Criteria in Solid Tumors; Oncology; Docetaxel; Progression-free survival; Phases of clinical research; Chemotherapy; Adverse effect; Randomization; Gastroenterology; Randomized controlled trial; Surgery; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001360486,0.001181573,0.001721107,0.0003449588,0.0004451314,0.001537711,0.001009059,0.001378102,0.007479543],"category_scores_gemma":[0.001014,0.0005565921,0.001727776,0.0002869476,0.0009939617,0.001051196,0.0003757591,0.004186025,0.001389741],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001253793,"about_ca_system_score_gemma":0.001300948,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002217604,"about_ca_topic_score_gemma":0.008864323,"domain_scores_codex":[0.9997413,0.0001007307,0.00001210436,0.00005527469,0.00002129124,0.00006920745],"domain_scores_gemma":[0.999461,0.00008397319,0.0000724544,0.00003944281,0.00002082055,0.0003223279],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8769936,0.02929781,0.003408266,0.0007667564,0.001475558,0.0001152483,0.0002190046,0.002656218,0.01403314,0.0004567842,0.008089057,0.06248851],"study_design_scores_gemma":[0.8472843,0.1417426,0.004860396,0.00003183054,0.0005812964,0.0001284324,0.00006432404,0.001343516,0.001231466,0.0003414669,0.002361464,0.00002900291],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901883,0.00181818,0.0002749972,0.0009688665,0.0004176703,0.001221517,0.002012302,0.0001618242,0.002936442],"genre_scores_gemma":[0.9865087,0.001324084,0.001179986,0.001481215,0.0002476704,0.001114619,0.003233769,0.00005216831,0.004857713],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007479543,"threshold_uncertainty_score":0.02502155,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1281038229884469,"score_gpt":0.4189531583647975,"score_spread":0.2908493353763506,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}